These investigations have led to the clinical use of anti-angiogenic agents, such as the anti-vascular endothelial growth factor (VEGF) antibody Bevacizumab for breast and other cancers [4]–[6], and small molecule tyrosine kinase inhibitors such as Sunitinib [7]. Here, VEGFA is linked to cancer.